Sage Therapeutics, Inc. (SAGE) Price Target Raised to $145.00 at Royal Bank of Canada
Sage Therapeutics, Inc. (NASDAQ:SAGE) had its price target raised by Royal Bank of Canada to $145.00 in a research note published on Thursday. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical company’s stock.
A number of other brokerages also recently issued reports on SAGE. Canaccord Genuity cut their target price on Sage Therapeutics from $110.00 to $81.00 and set a buy rating for the company in a research note on Tuesday, September 12th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $82.00 target price (down from $95.00) on shares of Sage Therapeutics in a research note on Wednesday, September 13th. Stifel Nicolaus started coverage on Sage Therapeutics in a research note on Wednesday, August 9th. They issued a buy rating and a $104.00 target price for the company. BMO Capital Markets raised their target price on Sage Therapeutics from $80.00 to $84.00 and gave the stock an outperform rating in a research note on Thursday, September 14th. Finally, Cowen and Company cut their target price on Sage Therapeutics from $100.00 to $90.00 and set an outperform rating for the company in a research note on Tuesday, September 12th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $99.86.
Shares of Sage Therapeutics (SAGE) traded down $0.61 during mid-day trading on Thursday, reaching $96.04. The company’s stock had a trading volume of 1,750,000 shares, compared to its average volume of 524,206. Sage Therapeutics has a 12 month low of $44.55 and a 12 month high of $98.80.
Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.98) by $0.01. The firm’s quarterly revenue was up .0% on a year-over-year basis. equities research analysts forecast that Sage Therapeutics will post -7.34 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of SAGE. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Sage Therapeutics by 11.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 138 shares during the last quarter. Hershey Trust Co. acquired a new stake in shares of Sage Therapeutics during the 3rd quarter worth about $118,000. Bessemer Group Inc. acquired a new stake in shares of Sage Therapeutics during the 3rd quarter worth about $141,000. Turner Investments LLC acquired a new stake in shares of Sage Therapeutics during the 2nd quarter worth about $159,000. Finally, Dubuque Bank & Trust Co. acquired a new stake in shares of Sage Therapeutics during the 2nd quarter worth about $167,000.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.